Webdisclosure.fr

Search

UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Directive transparence : information réglementée

19/04/2024 20:00
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3D_qyi_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3= TcTguEBAZULV5Uv0ChVpLboCUAX8ErGBohxDXMRgGarJcDzeHqeXxgFC-2Fn-2BbAC0ITia0N-2= FFxcn7TKuQb1KjI-2BfwCf-2BSJeR1-2FNB2bqgs-2BsMnou73eTKAh25Oov6Fii8caVd3xQTjf= ch7xd-2BeAMWO7liQheKdp4SeiGZaEF2jQS11v0hug-3D ** Acquisition of own shares ------------------------------------------------------------ Brussels (Belgium), 19 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate= d information=C2=A0 In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2024.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona= ry mandate agreement with initial validity until 30 June 2024, effective as= from 02 April 2024, to cover current and future obligations under UCB's Lo= ng Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2024, UCB repurchased 90,= 751 UCB shares on Euronext Brussels in the period from 12 April 2024 up to = and including 18 April 2024, as follows:=C2=A0 https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepYYZ4oC6FqiyL9RK4lKLxvgzCp3wwI4OcAGQ4JoUI9r8QfCpMxEF= Uyyx4wyBo1xpW6DQ14-2FZvKSVODZCasWDx-2F3hRQF_2dCLUNbuBjhX746-2FvM63L9Hyn3KnT= FGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIx= s8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94t= XHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLboCUAUaH5r6Z-2FW5NqMerJ6J-2BqBeqeCNs= SfVV9VojEkpoq70ckWc48NKShkm7lUCB45Uhcrs6NCZCrfy1vNy-2B-2Bn7h2R7bKk2x-2BH088= wF-2BwtqdlfA5jAe5pEQnYJ5VChK3jGf2jEqbCXEyT-2BuTuVJNTA-2F8j94-3D This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz= lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj= fTg-3D-3DwVH3_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI= fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV= 33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV= 5Uv0ChVpLboCUAbrbaddXOZj7x2KDzoiY99ZFMY6IYrNHA-2BhYPoo6ZNmN7xc1Osu29eHbbLFT= PCrhznLN-2Fj0oi3NfAouc9wCcWdGD8S8nA7gLDL86pr1PmwZBEabJcXfIMrs4vrgzNU-2BExqj= A2-2FgMNN7k9MEHdO7KXlM-3D . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 Antje.Witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 9,000 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll= ow us on Twitter: @UCB_news. =C2=A0 GenericFile 240419 - Verwerving van eigen aandelen NL Draft 002 (https://u7061146.ct.se= ndgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIH= epYYZ4oC6FqiyL9RK4lKLxvgFaHJIb4S-2B61qNMB2c-2BY8Sw7Edoc8CSI6AvLB8R6uybg-3Dd= wF8_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSa= z3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0Vyw= ZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLb= oCUAbJIzMUhdt0xrbjzOoXZclIULxeOmEOyGHTj0YoBZ6nGNE4-2Fnl321fUWB83G3p-2Bab1-2= FRs8mJ-2BrLxhrjrHw1COvG8hM-2FbGuwGEQ8pYjNuz5gqnUYT9TAGTpdqms6hywCoW-2BxwDdZ= 4l-2Fc9-2BHMvNSaVdKg-3D GenericFile 240419 - Acquisition actions propres FR Draft 002 (https://u7061146.ct.send= grid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHep= YYZ4oC6FqiyL9RK4lKLxvg9R7RqYdNsoZx57-2BMCBINe7S2rO4Efh-2BIoRc0aF-2FMmP4-3Do= RmL_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSa= z3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0Vyw= ZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLb= oCUAVuYsePNH5M4gRJA717Hz5rq2foBDF9YdTsy5zik0YoLLNFwGtwPsXeKHEN5wUdIZ4wFM0J1= wUjD3zM1jmTJ7CLPUIORCWWDylgXgm5JRv0Kot1bXZgDvhvMRiR37MhAZ8nkmPAPOxamq1Lgkxd= 8gfU-3D GenericFile 240419 - Acquisition of own shares ENG Draft (https://u7061146.ct.sendgrid.= net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepYYZ4o= C6FqiyL9RK4lKLxvgQ8K-2Fp9eDD4HJfP-2FwOiiyfmVuzWiUOsXN8r2FGJKQYso-3DpUpw_2dC= LUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcE= W6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0VywZiyWp2s= 5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLboCUAbDc= mY7O-2BINSYnV4hEy-2FUNPP1civv8T3WGjmNAi4pCg3bQ3nJ6waLhi6Oc79VjFeLq82NgGdrS6= PnDE7k5DVIHtLAo0r-2FQEr5JVgLEh2JssArYPjscKQBFpyWsVR6jL04gS2PcvA6AYuUPf83rSq= ch8-3D Image Chart 1 April 19 2024 (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001= .gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepYYZ4oC6FqiyL9RK4lKLxvgzCp3ww= I4OcAGQ4JoUI9r8ahIFoXCUigYDAG-2FeJI4lnw-3DcmlL_2dCLUNbuBjhX746-2FvM63L9Hyn3= KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93Dw= fIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy= 94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLboCUAep-2BQevq6CT29odz48tpFHctum3= aFymToUWvJ739o-2Bb9KEz5VMlxiMPd5deVMuGUWWByQi9Tj91VaqwAOGn5KEBPZ7wytKxUzARV= mlzszFTEsLLy6anyorL6GudhyPcBrAf9ic9bCDnyI7LDiB-2FlAG8-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNuwurjhdgMpIK83hhh217-2BO= i9yILcLIuhCr6QTkOeeClaRvgwcAZ9PlIfiihDLdkweJ01g42vwL2YFV9Goq66t-2FalIv9vSEQ= grExehy57yN8-3D6CeN_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2= nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6F= ohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguE= BAZULV5Uv0ChVpLboCUAQxM3t1io7ldwb5R9x17kEHFn041ZlLFVYmLYZiC2Fcmh2Y-2FV4Jrhl= 5ke2Qx-2BqxSj75cXGisqcoS1faAweV38auFwMtO9OmUp1O1qIRj40fgVAEuxt0DvJZwNgRYg41= IYBmhPOMUcayvwiVbvn9-2FFm8-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium